Review Article: Impact of Alcohol Consumption on the Development and Progression of Metabolic Dysfunction–Associated Steatotic Liver Disease
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70335 ↗At a glance
Übersichtsarbeit in Alimentary Pharmacology & Therapeutics, 2025. Written by Yunxuan Lei and 5 co-authors. Institution: Department of Infectious Disease, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China. Major MEDLINE topics: Alcohol Drinking, Fatty Liver. Cited 5 times so far (Crossref); 104 references. Funded by: Project supported by Medical Science and technology development Foundation, Nanjing Department of Health, Project of Institute of Chinese Medicine, Nanjing University/Aid Project of Nanjing Drum Tower Hospital Health, Education & Research Foundation, Nanjing science and technology bureau 2024 International/Hong Kong/Macau/Taiwan Science and Technology Cooperation Project.
Abstract (original language)
Background
Metabolic dysfunction–associated steatotic liver disease (MASLD) is recognised as a globally prevalent chronic liver disease, primarily driven by metabolic risk factors such as insulin resistance, obesity, dyslipidaemia and impaired glucose metabolism. Traditionally considered distinct from alcohol‐related liver disease, MASLD is increasingly being re‐evaluated in light of new evidence regarding the role of alcohol consumption.
Aims
To clarify the multifaceted effects of alcohol intake on the progression of MASLD. We focus on the underlying pathophysiological mechanisms, clinical implications and the challenges associated with risk stratification in affected individuals.
Methods
We conducted a narrative review of epidemiological and mechanistic studies on the interaction between alcohol intake and metabolic dysfunction in MASLD up to 30 June 2025.
Results
Accumulating evidence indicates that even moderate alcohol consumption can amplify hepatic steatosis through multiple interconnected mechanisms, including oxidative stress, disrupted lipid metabolism and gut microbiota dysbiosis. These changes trigger inflammatory cascades and accelerate the progression from simple steatosis to steatohepatitis, fibrosis and cirrhosis in individuals with underlying metabolic dysfunction. Epidemiological studies have revealed a dose‐dependent relationship between alcohol intake and liver disease severity, with synergistic effects particularly evident in patients with obesity or metabolic syndrome.
Conclusions
Alcohol amplifies MASLD progression through synergistic mechanisms. Standardised evaluation of alcohol use is critical for risk stratification and the development of personalised treatment strategies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Infectious Disease, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
- Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- Department of Translational Medicine Center, Affiliated Hospital of Hangzhou Normal University, Institute of Hepatology and Metabolic Diseases, Hangzhou Normal University, Hangzhou, China.
- Department of Medicine and State Key Laboratory of Liver Research, the University of Hong Kong, Hong Kong, China.
ORCID profiles: Wenjing Ni, Junping Shi, Wai-Kay Seto, Jie Li
Funding
- Project supported by Medical Science and technology development Foundation, Nanjing Department of Health
- Project of Institute of Chinese Medicine, Nanjing University/Aid Project of Nanjing Drum Tower Hospital Health, Education & Research Foundation
- Nanjing science and technology bureau 2024 International/Hong Kong/Macau/Taiwan Science and Technology Cooperation Project
- Nanjing Drum Tower Hospital Clinical Research Special Fund project (No. 2024-LCYJ-PY-53)
Cite
APA
Lei, Y., Zhu, Y., Ni, W., Shi, J., Seto, W. K., & Li, J. (2025). Review Article: Impact of Alcohol Consumption on the Development and Progression of Metabolic Dysfunction–Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70335
Vancouver
Lei Y, Zhu Y, Ni W, Shi J, Seto WK, Li J. Review Article: Impact of Alcohol Consumption on the Development and Progression of Metabolic Dysfunction–Associated Steatotic Liver Disease. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70335
BibTeX
@article{Lei2025,
author = {Lei, Yunxuan and Zhu, Yixuan and Ni, Wenjing and Shi, Junping and Seto, Wai-Kay and Li, Jie},
title = {Review Article: Impact of Alcohol Consumption on the Development and Progression of Metabolic Dysfunction–Associated Steatotic Liver Disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70335}
}
EUVIMED